CoChat
Sign Up
Cited by 48Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Open access
Tan, Rachel H., Kril, Jillian J., Yang, Yue, Tom, Nicole, Hodges, John R., Villemagne, Victor L., Rowe, Christopher C., Leyton, Cristian E. +3 more·2017·Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
DOI 10.1016/j.dadm.2017.05.005PMC PMC5473545
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. Methods: Aβ was assessed in 98 autopsy‐confirmed FTD and 36 control cases, and the pathological accuracy of 11 C‐Pittsburgh compound B (PiB)–positron emission tomography imaging was assessed in a subset of FTD cases (n = 15). Results: Aβ was identified in a similar proportion of FTD syndromes and age‐matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter. Discussion: The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2017.05.005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Primary tauopathy patients do not generally have substantial Aβ burden in their brains.

    “While this is somewhat incongruous with the observations from primary tauopathy patients who do not generally have substantial Aβ burden in their brains (36), whether tau tangles and associated neurotoxicity (such as neuroinflammation and oxidative stress) in specific brain areas drive amyloid deposits could be examined in the future.”

    From Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation (2022) · cites this paper as [36]

    The Results report no Aβ deposition in the four FTD patients with a MAPT mutation, and a separate Results comparison finds substantially lower cortical Aβ burden in FTD than in Alzheimer’s disease. These findings support the point for the studied patients, but the paper does not establish it for primary tauopathies generally. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [1]Chare L. Hodges J.R. Leyton C.E. McGinley C. Tan R.H. Kril J.J. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications J Neurol Neurosurg Psychiatry 85 2014 865 870 24421286
  2. [2]Shelley B.P. Hodges J.R. Kipps C.M. Xuereb J.H. Bak T.H. Is the Pathology of Corticobasal Syndrome Predictable in Life? Movement Disord 24 2009 1593 1599 19533751
  3. [3]Dubois B. Feldman H.H. Jacova C. Hampel H. Molinuevo J.L. Blennow K. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629 24849862
  4. [4]Ikonomovic M.D. Klunk W.E. Abrahamson E.E. Mathis C.A. Price J.C. Tsopelas N.D. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645 18339640 PMC2408940
  5. [5]Lockhart A. Lamb J.R. Osredkar T. Sue L.I. Joyce J.N. Ye L. PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis Brain 130 2007 2607 2615 17698496
  6. [6]Niedowicz D.M. Beckett T.L. Matveev S. Weidner A.M. Baig I. Kryscio R.J. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease Ann Neurol 72 2012 564 570 23109151 PMC3490445
  7. [9]Mirra S.S. Heyman A. McKeel D. Sumi S.M. Crain B.J. Brownlee L.M. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486 2011243
  8. [10]Rascovsky K. Hodges J.R. Knopman D. Mendez M.F. Kramer J.H. Neuhaus J. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia Brain 134 2011 2456 2477 21810890 PMC3170532
  9. [11]Brooks B.R. Miller R.G. Swash M. Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis Amyotroph Lateral Scler Other Mot Neuron Disord 1 2000 293 299 11464847
  10. [12]Mackenzie I.R. Neumann M. Baborie A. Sampathu D.M. Du Plessis D. Jaros E. A harmonized classification system for FTLD-TDP pathology Acta Neuropathol 122 2011 111 113 21644037 PMC3285143
  11. [13]Ahmed Z. Bigio E.H. Budka H. Dickson D.W. Ferrer I. Ghetti B. Globular glial tauopathies (GGT): consensus recommendations Acta Neuropathol 126 2013 537 544 23995422 PMC3914659
  12. [14]Dickson D.W. Neuropathology of Pick's disease Neurology 56 2001 S16 S20 11402145
  13. [15]Dickson D.W. Bergeron C. Chin S.S. Duyckaerts C. Horoupian D. Ikeda K. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration J Neuropathol Exp Neurol 61 2002 935 946 12430710
  14. [16]Hauw J.J. Daniel S.E. Dickson D. Horoupian D.S. Jellinger K. Lantos P.L. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology 44 1994 2015 2019 7969952
  15. [17]Tan R.H. Kril J.J. Fatima M. McGeachie A. McCann H. Shepherd C. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes Brain 138 2015 3110 3122 26231953
  16. [18]Leyton C.E. Villemagne V.L. Savage S. Pike K.E. Ballard K.J. Piguet O. Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using beta-amyloid imaging Brain 134 2011 3030 3043 21908392
  17. [19]Rowe C.C. Ellis K.A. Rimajova M. Bourgeat P. Pike K.E. Jones G. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283 20472326
  18. [20]Villemagne V.L. Burnham S. Bourgeat P. Brown B. Ellis K.A. Salvado O. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367 23477989
  19. [21]Thal D.R. Rub U. Orantes M. Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800 12084879
  20. [22]Tan R.H. Wong S. Kril J.J. Piguet O. Hornberger M. Hodges J.R. Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia Brain 137 2014 2065 2076 24844729
  21. [23]Glodzik L. Rusinek H. Kamer A. Pirraglia E. Tsui W. Mosconi L. Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects Alzheimers Dement (Amst) 2 2016 95 104 27239540 PMC4879519
  22. [24]Jagust W. Is amyloid-beta harmful to the brain? Insights from human imaging studies Brain 139 2016 23 30 26614753 PMC4990654
  23. [25]Jack C.R. Therneau T.M. Wiste H.J. Weigand S.D. Knopman D.S. Lowe V.J. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study Lancet Neurol 15 2016 56 64 26597325 PMC4784263
  24. [26]Driscoll I. Troncoso J.C. Rudow G. Sojkova J. Pletnikova O. Zhou Y. Correspondence between in vivo C-11-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques Acta Neuropathol 124 2012 823 831 22864813 PMC3566238
  25. [27]Murray M.E. Lowe V.J. Graff-Radford N.R. Liesinger A.M. Cannon A. Przybelski S.A. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum Brain 138 2015 1370 1381 25805643 PMC4407190
  26. [28]Sojkova J. Driscoll I. Iacono D. Zhou Y. Codispoti K.E. Kraut M.A. In vivo fibrillar beta-amyloid detected using [C-11]PiB positron emission tomography and neuropathologic assessment in older adults Arch Neurol-chicago 68 2011 232 240 21320990 PMC3082956
  27. [29]Perry D.C. Lehmann M. Yokoyama J.S. Karydas A. Lee J.J. Coppola G. Progranulin mutations as risk factors for Alzheimer disease JAMA Neurol 70 2013 774 778 23609919 PMC3743672
  28. [31]Bateman R.J. Xiong C. Benzinger T.L. Fagan A.M. Goate A. Fox N.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease New Engl J Med 367 2012 795 804 22784036 PMC3474597
  29. [32]Jansen W.J. Ossenkoppele R. Knol D.L. Tijms B.M. Scheltens P. Verhey F.R.J. Prevalence of cerebral amyloid pathology in persons without dementia a meta-analysis JAMA 313 2015 1924 1938 25988462 PMC4486209
  30. [33]Jack C.R. Knopman D.S. Jagust W.J. Petersen R.C. Weiner M.W. Aisen P.S. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216 23332364 PMC3622225
  31. [35]Engler H. Santillo A.F. Wang S.X. Lindau M. Savitcheva I. Nordberg A. In vivo amyloid imaging with PET in frontotemporal dementia Eur J Nucl Med Mol Imaging 35 2008 100 106 17846768
  32. [36]Villeneuve S. Rabinovici G.D. Cohn-Sheehy B.I. Madison C. Ayakta N. Ghosh P.M. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation Brain 138 2015 2020 2033 25953778 PMC4806716

Cited by

Sorted by citations

Authors
Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., Rowe, C. C., Leyton, C. E., Kwok, J. B. J., Ittner, L. M., & Halliday, G. M.
Affiliations
  • The University of Sydney (AU)
  • Neuroscience Research Australia (AU)
  • Austin Health (AU)
  • UNSW Sydney (AU)
Corresponding author
Tan, Rachel H.
ORCID
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2017-01
Volume
9
Issue
1
Pages
10-20
ISSN
2352-8729 (ISSN-L)
DOI
10.1016/j.dadm.2017.05.005
PMC
PMC5473545
OpenAlex
W2617540477
Cited by
48
References
4
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 9 · 2017: 2
FWCI
5.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • The Sydney eScholarship Repository (The University of Sydney) (submittedVersion, cc-by-nc-nd)
Funders
  • University of New South Wales
  • Neuroscience Research Australia
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
amyloid-beta, frontotemporal dementia, Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, autopsy confirmation, amyloid pathology, diagnostic accuracy, white matter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review